OverviewSuggest Edit

Interpace Diagnostics is a health care commercialization company providing insight-driven, integrated multi-channel message delivery for health care companies. The Company is focused on developing and commercializing molecular diagnostic tests principally focused on early detection of high potential progressors to cancer and leveraging the latest technology and personalized medicine for patient diagnosis and management. Through its molecular diagnostics business, the Company provides diagnostic options for detecting genetic and other molecular alterations that are associated with gastrointestinal and endocrine cancers, which are focused on early detection of cancer.

... Show more
TypePublic
Founded1987
HQParsippany-Troy Hills, US
Websiteinterpacediagnostics.com

Latest Updates

Employees (est.) (Feb 2019)75(+23%)
Revenue (FY, 2017)$15.9 M(+22%)
Share Price (Feb 2019)$1 (+2%)

Interpace Diagnostics Office Locations

Interpace Diagnostics has an office in Parsippany-Troy Hills
Parsippany-Troy Hills, US (HQ)
300 Interpace Pkwy
Show all (1)
Report incorrect company information

Interpace Diagnostics Financials and Metrics

Interpace Diagnostics Revenue

Embed Graph
View revenue for all periods
Interpace Diagnostics's revenue was reported to be $15.90 m in FY, 2017
USD

Revenue (Q3, 2018)

5.8m

Gross profit (Q3, 2018)

3.0m

Gross profit margin (Q3, 2018), %

52%

Net income (Q3, 2018)

(3.0m)

EBIT (Q3, 2018)

(2.5m)

Market capitalization (13-Feb-2019)

27.9m

Closing stock price (13-Feb-2019)

1.0

Cash (30-Sep-2018)

8.0m
Interpace Diagnostics's current market capitalization is $27.9 m.
Annual
USDFY, 2013FY, 2014FY, 2015FY, 2016FY, 2017

Revenue

150.8m119.9m9.4m13.1m15.9m

Revenue growth, %

(20%)(92%)39%

Cost of goods sold

126.4m101.4m6.9m6.6m7.4m

Gross profit

24.4m18.5m2.5m6.4m8.5m
Quarterly
USDQ3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018

Revenue

34.3m32.8m31.6m29.2m38.3m36.3m36.6m3.0m3.6m3.3m3.5m3.9m4.2m4.8m5.5m5.8m

Cost of goods sold

29.6m27.7m26.8m25.5m30.7m30.2m29.4m1.2m1.8m1.8m1.8m1.9m2.1m2.6m2.2m2.8m

Gross profit

4.7m5.1m4.8m3.7m7.6m6.1m7.2m1.9m1.8m1.5m1.7m2.0m2.1m2.2m3.3m3.0m

Gross profit Margin, %

14%16%15%13%20%17%20%61%49%44%49%51%51%46%59%52%
Annual
USDFY, 2013FY, 2014FY, 2015FY, 2016FY, 2017

Cash

45.6m23.1m8.3m602.0k15.2m

Accounts Receivable

2.4m8.5m2.8m2.2m3.4m

Current Assets

62.7m44.9m19.2m4.2m19.8m

PP&E

2.8m3.2m1.5m929.0k654.0k
Quarterly
USDQ3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018

Cash

49.6m37.9m35.6m27.0m17.0m14.4m9.0m4.3m3.0m1.7m7.1m14.3m11.7m12.6m10.1m8.0m

Accounts Receivable

4.0m8.5m3.8m3.4m13.4m11.9m12.3m2.8m3.0m2.8m2.3m2.7m2.8m6.4m7.6m8.6m

Current Assets

66.5m59.0m53.2m42.2m43.1m39.3m32.1m11.7m9.6m6.7m10.7m18.3m15.8m20.1m19.2m18.2m

PP&E

3.1m2.8m2.8m2.9m3.3m3.1m2.8m1.3m1.2m1.1m770.0k644.0k668.0k634.0k640.0k859.0k
Annual
USDFY, 2013FY, 2014FY, 2015FY, 2016FY, 2017

Net Income

(4.6m)(16.1m)(11.4m)(8.3m)(12.2m)

Depreciation and Amortization

1.4m4.5m3.7m

Accounts Payable

143.0k(2.6m)

Cash From Operating Activities

(3.5m)(16.4m)(19.8m)(8.9m)(15.3m)
Quarterly
USDQ3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018

Net Income

(899.0k)(1.6m)(4.3m)(8.6m)(3.9m)(10.8m)(15.7m)(4.8m)(7.1m)(7.5m)2.4m(3.9m)(7.2m)(3.2m)(5.1m)(8.2m)

Depreciation and Amortization

922.0k457.0k837.0k1.3m2.5m3.8m1.3m2.4m972.0k1.9m2.8m855.0k1.7m2.6m

Accounts Payable

143.0k2.1m2.9m3.0m42.0k200.0k1.2m(1.1m)1.4m295.0k344.0k782.0k674.0k

Cash From Operating Activities

237.0k(6.5m)(8.3m)(8.0m)(8.1m)(13.5m)(4.0m)(5.3m)(4.1m)(8.7m)(12.9m)(2.5m)(5.0m)(6.8m)
USDY, 2018

Financial Leverage

1.4 x
Show all financial metrics

Interpace Diagnostics Operating Metrics

FY, 2016

Facilities

2

Patent Applications

16

Patents (Foreign)

3

Products

3
Show all operating metrics
Report incorrect company information

Interpace Diagnostics Online and Social Media Presence

Embed Graph
Report incorrect company information

Interpace Diagnostics News and Updates

Interpace Diagnostics to Attend BIO CEO & Investor Conference in New York City

PARSIPPANY, NJ, Feb. 04, 2019 (GLOBE NEWSWIRE) -- Interpace Diagnostics Group (NASDAQ: IDXG) today announced the Company will attend the 21st BIO CEO & Investor Conference being held in New York, NY at the New York Marriott Marquis on February 11th & 12th, 2019. The Company will host one-…

Interpace Diagnostics Announces Proposed Public Offering of Common Stock

PARSIPPANY, N.J., Jan. 24, 2019 (GLOBE NEWSWIRE) -- Interpace Diagnostics Group, Inc. (Nasdaq: IDXG) (“Interpace” or the “Company”) announced today that it intends to offer and sell shares of its common stock in a registered underwritten public offering. In addition, Interpace also intends to gra…

Interpace Diagnostics to Present at the Fifteenth Annual NobleCon

PARSIPPANY, NJ, Jan. 24, 2019 (GLOBE NEWSWIRE) -- Interpace Diagnostics Group (NASDAQ: IDXG) today announced that Jack Stover, Chief Executive Officer, will present at NobleConXV - Noble Capital Markets’ Fifteenth Annual Investor Conference at the W Hotel, Fort Lauderdale, Florida - on Tuesday, J…

Interpace Diagnostics Announces Further Expansion of Thyroid Business

Interpace Only Provider Validated to Offer MDx Tests on Three Distinct Platforms

Interpace Diagnostics Enters into Agreement with University of Maryland Medical Systemwdxefcqufszuzezftuxetqsqxt

Agreement Provides Access to Company’s Available Molecular Diagnostic Tests

Interpace Diagnostics Ranked as Top 10 Bioinformatics Solutions Provider

PARSIPPANY, NJ, Dec. 27, 2018 (GLOBE NEWSWIRE) -- Interpace Diagnostics Group, Inc. (NASDAQ: IDXG) announced today that CIO Applications, a publication focused on providing professionals with information on the most comprehensive collection of technology trends, has once again recognized Interpac…
Show more
Report incorrect company information

Interpace Diagnostics Blogs

Interpace Diagnostics Reports Third Quarter 2018 Financial Results, Business Progress and Recent Accomplishments

Conference Call Tuesday, November 13, 2018 at 4:30 pm ET PARSIPPANY, NJ,, Nov. 13, 2018 (GLOBE NEWSWIRE) -- Interpace Diagnostics Group, Inc. IDXG, +0.84% a fully integrated commercial and bioinformatics company that provides clinically useful molecular diagnostic tests and pathology services for im…

Interpace Diagnostics to Host Conference Call and Webcast to Discuss Third Quarter 2018 Financial Results on Tuesday, November 13, 2018

Interpace Diagnostics Group, Inc. IDXG, +1.48% announced today that it will report its third quarter 2018 financial results after the close of market on Tuesday, November 13, 2018 at 4:30 p.m. ET. Following the announcement, Interpace will host a conference call and webcast to discuss the Company's …

Interpace Diagnostics Presents Favorable New Data at the 88th Annual Meeting of the American Thyroid Association (ATA)

ThyGenX® and ThyraMIR® Data from Clinical Experience Study Shows Positive Results  PARSIPPANY, NJ, Oct. 15, 2018 (GLOBE NEWSWIRE) -- Interpace Diagnostics Group, Inc. IDXG, +1.47% announced that the Company presented new data at the 88th Annual Meeting of the American Thyroid Association (ATA) on Fr…

Interpace Diagnostics CEO Provides Corporate Update

Interpace Diagnostics Group IDXG, -6.15% is pleased to provide a corporate update to shareholders on current business activities from its Chief Executive Officer, Jack Stover.   "I would like to share my gratitude for each of you and my confidence and pride in the future of Interpace Diagnostics Gro…

Interpace Diagnostics to Present New Data at the 88th Annual Meeting of the American Thyroid Association (ATA) on October 5th

ThyGenX® and ThyraMIR® Data from Clinical Experience Study to be Featured at ATA Product Expo  PARSIPPANY, NJ, Oct. 01, 2018 (GLOBE NEWSWIRE) -- Interpace Diagnostics Group, Inc. IDXG, +8.44% announced today that it will be presenting new data from a multi-center Clinical Experience Study at the 88t…

Interpace Diagnostics Supports Research Efforts of Pancreatic and Thyroid Cancer Patient Advocacy Groups

Interpace Employees Participate in Local Events in Support of Lustgarten Foundation for Pancreatic Cancer Research, Thyroid, Head and Neck Cancer Foundation, and Pancreatic Cancer Action Network  PARSIPPANY, NJ, Sept. 17, 2018 (GLOBE NEWSWIRE) -- Interpace Diagnostics Group, Inc. IDXG, +2.11% ("Inte…
Show more

Interpace Diagnostics Company Life and Culture

Report incorrect company information

Interpace Diagnostics Frequently Asked Questions

  • When was Interpace Diagnostics founded?

    Interpace Diagnostics was founded in 1987.

  • How many employees does Interpace Diagnostics have?

    Interpace Diagnostics has 75 employees.

  • What is Interpace Diagnostics revenue?

    Latest Interpace Diagnostics annual revenue is $15.9 m.

  • What is Interpace Diagnostics revenue per employee?

    Latest Interpace Diagnostics revenue per employee is $212 k.

  • Who are Interpace Diagnostics competitors?

    Competitors of Interpace Diagnostics include Althea, Egalet and LakePharma.

  • Where is Interpace Diagnostics headquarters?

    Interpace Diagnostics headquarters is located at 300 Interpace Pkwy, Parsippany-Troy Hills.

  • Where are Interpace Diagnostics offices?

    Interpace Diagnostics has an office in Parsippany-Troy Hills.

  • How many offices does Interpace Diagnostics have?

    Interpace Diagnostics has 1 office.